Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

7 results
Display

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide

Shim M, Bang WJ, Oh CY, Lee YS, Cho JS

PURPOSE: To investigate the changes in testosterone levels and rates of chemical castration following androgen-deprivation therapy (ADT) with goserelin, triptorelin, and leuprolide. MATERIALS AND METHODS: We retrospectively reviewed the medical records...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

Abdel Azim H, Kassem L, Shohdy KS, Eshaak B, Anis SE, Kamal NS

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study

Heo JY, Yi H, Fava M, Mischoulon D, Kim K, Yoon S, Jeon HJ, Lee JE

OBJECTIVE: Tamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression and anxiety and increase follicle-stimulating hormone (FSH) to patients. We compared anxiety...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea

Zhou J, Wu SG, Wang JJ, Sun JY, Li FY, Lin Q, Lin HX, He ZY

PURPOSE: The purpose of this study was to assess the value of ovarian ablation using goserelin in premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea (CIA). MATERIALS...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pathologic Changes in Uterine Leiomyomas Treated by GnRH Agonist Goserelin

Ju ES, Kim IG, Oh YE, Cho YL

  • KMID: 2270061
  • Korean J Obstet Gynecol.
  • 2001 Feb;44(2):263-267.
OBJECTIVE: To define the pathologic changes underlying the mechanism of shrinkage of uterine leimyoma in patients treated with goserelin. METHODS: Retrospective evaluation of pathologic changes seen in leiomyoma removed by hysterectomy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intermittent Androgen Deprivation with Goserelin and Flutamide for Prostate Cancer: a Pilot Study

Jeon SS, Choi HY

  • KMID: 2290125
  • Korean J Urol.
  • 1999 Oct;40(10):1295-1300.
PURPOSE: The purpose of this study was to evaluate the feasibility of using intermittent androgen deprivation(IAD) in patients with prostate cancer. MATERIALS AND METHODS: We reviewed the medical records of 29...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Combined Treatment of Tamoxifen, Goserelin, and Sulindac in 2 Cases of Recurrent Desmoid Tumor in the Abdomen

Kim HC, Suh BS, Lee DH, Ahn BY, Chung CS, Kang GH, Ha HK, Kim JC

  • KMID: 2142366
  • J Korean Soc Coloproctol.
  • 1999 Oct;15(4):339-343.
Desmoid tumor is a subtype of fibromatosis arising from deep fascial or soft tissue structure. It is characterized by locally aggressive behavior with a tendency to local recurrence, but is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr